Privia Health Eyes 12% Q4 Revenue Growth After Q3’s $580.4M Beat
Privia Health reported Q3 revenues of $580.4 million, a 32.5% year-over-year increase that surpassed analysts’ EPS and revenue forecasts. For Q4, analysts project 12% revenue growth year-over-year and maintain a $31.25 average price target versus a $21.70 share price.
1. Third-Quarter Performance
Privia Health delivered Q3 revenues of $580.4 million, a 32.5% rise year-over-year, topping consensus on both sales and EPS and marking its largest revenue beat in recent quarters.
2. Fourth-Quarter Outlook
Analysts forecast Q4 revenues to grow 12% year-over-year, improving from a 4.6% gain in the same quarter last year, with estimates largely reaffirmed ahead of the earnings release scheduled before market open.
3. Peer Comparisons and Analyst Targets
Within the healthcare technology segment, peers reported Q4 revenue changes ranging from a 27.5% decline to a 2.3% increase, while Privia’s shares have dropped 5.4% over the past month versus a 1.1% segment decline, and analysts’ average price target stands at $31.25 against the current $21.70 share price.